Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157

1.

The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.

Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators.

Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514. [Epub ahead of print]

PMID:
28892558
2.

Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.

Abdel-Hameed EA, Rouster SD, Zhang X, Chen J, Medvedovic M, Goodman ZD, Sherman KE.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):353-358. doi: 10.1097/QAI.0000000000001256.

PMID:
27898525
3.

Phenotypes and Pathology of Drug-Induced Liver Disease.

Goodman ZD.

Clin Liver Dis. 2017 Feb;21(1):89-101. doi: 10.1016/j.cld.2016.08.006. Epub 2016 Oct 18. Review.

PMID:
27842777
4.

Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D.

Ultrasound Q. 2016 Jun;32(2):94-107. doi: 10.1097/RUQ.0000000000000209. No abstract available.

PMID:
27233069
5.

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial.

Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, Kottilil S, Kovacs JA, Morse CG.

Liver Int. 2016 Dec;36(12):1783-1792. doi: 10.1111/liv.13177. Epub 2016 Jul 6.

PMID:
27232579
6.

Epidemiology and natural history of non-alcoholic fatty liver disease.

Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM.

Metabolism. 2016 Aug;65(8):1017-25. doi: 10.1016/j.metabol.2016.01.012. Epub 2016 Jan 29. Review.

PMID:
26997539
7.

Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

Patel K, Tillmann HL, Matta B, Sheridan MJ, Gardner SD, Shackel NA, McHutchison JG, Goodman ZD.

Aliment Pharmacol Ther. 2016 Feb;43(3):356-63. doi: 10.1111/apt.13471. Epub 2015 Nov 11.

8.

Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement.

Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D.

Radiology. 2015 Sep;276(3):845-61. doi: 10.1148/radiol.2015150619. Epub 2015 Jun 16.

PMID:
26079489
9.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.

Bedossa P, Burt AD, Brunt E, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2015 Apr;46(4):635-6. doi: 10.1016/j.humpath.2014.10.030. Epub 2014 Dec 31. No abstract available.

PMID:
25732109
10.

Correlates of adiponectin in hepatitis C-infected children: the importance of body mass index.

Delgado-Borrego A, Gonzalez-Peralta RP, Raza R, Negre B, Goodman ZD, Jonas MM, Chung RT, Ludwig DA; PEDS-C Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2015 Feb;60(2):165-70. doi: 10.1097/MPG.0000000000000604.

PMID:
25313851
11.

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

Nielsen MJ, Veidal SS, Karsdal MA, ├śrsnes-Leeming DJ, Vainer B, Gardner SD, Hamatake R, Goodman ZD, Schuppan D, Patel K.

Liver Int. 2015 Feb;35(2):429-37. doi: 10.1111/liv.12700. Epub 2014 Oct 29.

PMID:
25308921
12.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category.

Bedossa P, Burt AD, Brunt EM, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR.

Hum Pathol. 2014 Mar;45(3):658-60. doi: 10.1016/j.humpath.2013.09.020. Epub 2013 Nov 21. No abstract available.

PMID:
24529331
13.

Pathology of the liver sinusoids.

Brunt EM, Gouw AS, Hubscher SG, Tiniakos DG, Bedossa P, Burt AD, Callea F, Clouston AD, Dienes HP, Goodman ZD, Roberts EA, Roskams T, Terracciano L, Torbenson MS, Wanless IR.

Histopathology. 2014 Jun;64(7):907-20. doi: 10.1111/his.12364. Epub 2014 Mar 8. Review.

PMID:
24393125
14.

The impact of obesity on liver histology.

Goodman ZD.

Clin Liver Dis. 2014 Feb;18(1):33-40. doi: 10.1016/j.cld.2013.09.010. Epub 2013 Oct 25. Review.

PMID:
24274863
15.

Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study.

Mohan P, Barton BA, Narkewicz MR, Molleston JP, Gonzalez-Peralta RP, Rosenthal P, Murray KF, Haber B, Schwarz KB, Goodman ZD.

Hepatology. 2013 Nov;58(5):1580-6. doi: 10.1002/hep.26519. Epub 2013 Sep 30.

16.

Improvement in liver histology among Asian patients with chronic hepatitis B after long-term treatment with entecavir.

Tong MJ, Kowdley KV, Pan C, Hu KQ, Chang TT, Han KH, Yoon SK, Goodman ZD, Beebe S, Iloeje U, Tang H.

Liver Int. 2013 Apr;33(4):650-1. doi: 10.1111/liv.12121. No abstract available.

PMID:
23489906
17.

Inflammatory pseudotumor of the liver: a rare but distinct tumor-like lesion.

Balabaud C, Bioulac-Sage P, Goodman ZD, Makhlouf HR.

Gastroenterol Hepatol (N Y). 2012 Sep;8(9):633-4. No abstract available.

18.

Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis.

Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT; HALT-C Trial Group.

PLoS One. 2012;7(2):e27144. doi: 10.1371/journal.pone.0027144. Epub 2012 Feb 16.

19.

Genetics and imaging of hepatocellular adenomas: 2011 update. Invited commentary.

Ros PR, Goodman ZD.

Radiographics. 2011 Oct;31(6):1543-5; discussion 1545. No abstract available.

PMID:
22103002
20.

Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.

Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS; HALT-C Trial Group.

Hepatology. 2011 Nov;54(5):1527-37. doi: 10.1002/hep.24550.

Supplemental Content

Loading ...
Support Center